5 assets in Cystic Fibrosis-Related Diabetes

Therapeutic assets addressing Cystic Fibrosis-Related Diabetes, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Semaglutide Cystic Fibrosis-Related Diabetes	University of Minnesota	P2/3	B (60)
Empagliflozin Cystic Fibrosis-Related Diabetes	University of Minnesota	P2/3	B (57)
Metformin Cystic Fibrosis-Related Diabetes	University of Kansas Medical Center	P2	CCC (53)
Glucose, Anhydrous Cystic Fibrosis-Related Diabetes	Children's Hospital of Philadelphia	Early P1	CCC (51)
Dorzagliatin Cystic Fibrosis-Related Diabetes	University of Pennsylvania	P1	CC (43)